Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 35Carboplatin 24Specimen Handling 20Cyclophosphamide 18Magnetic Resonance Spectroscopy 17fludarabine 15Nivolumab 14Dexamethasone 14Bevacizumab 14Gemcitabine 12Biopsy 12atezolizumab 11Temozolomide 11Paclitaxel 10venetoclax 9Pemetrexed 9Ipilimumab 9Docetaxel 9Cisplatin 9Rituximab 8Lenalidomide 8blinatumomab 7Prednisone 7Oxaliplatin 7Fluorouracil 7Capecitabine 7olaparib 6lenvatinib 6Vincristine 6Radiotherapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × naxitamab × 30 days × Clear all
NCT07011654 2026-05-20

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
31 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡